Recurrent Childhood Acute Lymphoblastic Leukemia Recruiting Phase 2 Trials for DB05889 (Inotuzumab ozogamicin)

IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs